Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4559306 | 0.89 | HTR1A (0.41) | GRIA1ALDH1A1TSHRPOLBAR | |
| SCHEMBL4473337 | 0.89 | GRIA1 (0.39) | GRIA1ALDH1A1MAPK1KMT2AMEN1 | |
| SCHEMBL4489790 | 0.89 | GRIA1 (0.39) | GRIA1ALDH1A1MAPK1KMT2AMEN1 | |
| SCHEMBL4495976 | 0.89 | HTR1A (0.41) | GRIA1ALDH1A1TSHRPOLBAR | |
| SCHEMBL4704134 | 0.86 | HPGD (0.50) | HPGDALDH1A1NPC1RAB9ATSHR | |
| SCHEMBL4491107 | 0.84 | HPGD (0.50) | HPGDALDH1A1KMT2ATSHRPOLB | |
| SCHEMBL4498044 | 0.81 | ALPL (0.46) | GRIA1AR | |
| SCHEMBL4489627 | 0.81 | CYP19A1 (0.45) | GRIA1KMT2AMEN1AR | |
| SCHEMBL4492290 | 0.81 | CHRNB4 (0.42) | GRIA1ALDH1A1KMT2AMEN1NPC1 | |
| SCHEMBL5986573 | 0.81 | CYP19A1 (0.45) | GRIA1KMT2AMEN1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504390-B2 | Benzoxazepine derivatives and their use as AMPA receptor stimulators | N.V. ORGANON (NL) | 2009-03-17 | — | — | US | disclosed |
| US-20080139529-A1 | BENZOXAPZEPINE DERIVATIVES AND THEIR USE AS AMPA RECEPTOR STIMULATORS | N.V. ORGANON (NL) | 2008-06-12 | — | — | US | disclosed |
| EP-1399450-B1 | BENZOXAZEPINE DERIVATIVES AND THEIR USE AS AMPA RECEPTOR STIMULATORS | ORGANON NV (NL) | 2008-03-19 | — | — | EP | disclosed |
| US-7307073-B2 | Benzoxazepines derivatives and their use as AMPA receptor stimulators | N.V. ORGANON (NL) | 2007-12-11 | — | — | US | disclosed |
| US-20040171605-A1 | Benzoxazepines derivatives and their use as ampa receptor stimulators | MERCK SHARP & DOHME B.V. (NL) | 2004-09-02 | — | — | US | disclosed |
| EP-1399450-A1 | BENZOXAZEPINE DERIVATIVES AND THEIR USE AS AMPA RECEPTOR STIMULATORS | Akzo Nobel N.V. (NL) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002100865-A1 | BENZOXAZEPINE DERIVATIVES AND THEIR USE AS AMPA RECEPTOR STIMULATORS | AKZO NOBEL N.V. (NL) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171605-A1 | Benzoxazepines derivatives and their use as ampa receptor stimulators | CHRNA4, CHRNA10, CHRNA9 | HPGD 1789/4885GRIA1 19/4885ALDH1A1 2962/4885 |
| US-20080139529-A1 | BENZOXAPZEPINE DERIVATIVES AND THEIR USE AS AMPA RECEPTOR STIMULATORS | GRIN1, GRIA4, CHRNA4 | HPGD 2047/4885GRIA1 10/4885ALDH1A1 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.